Kura Oncology (KURA) Enterprise Value (2010 - 2026)
Kura Oncology (KURA) reported Enterprise Value of -$580.8 million for Q1 2026, up 11.75% year-over-year from -$519.7 million in Q1 2025, and up 12.95% quarter-over-quarter from -$667.2 million in Q4 2025.
Kura Oncology (KURA) Enterprise Value (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has 17 years of Enterprise Value data on file, last reported at -$580.8 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$580.8 million, up 11.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$580.8 million (up 11.75% YoY), and the FY2025 annual result was -$667.2 million, up 8.27% from the prior year.
- Enterprise Value advanced to -$580.8 million in Q1 2026 per KURA's latest filing, from -$667.2 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$405.9 million in Q1 2023 and troughed at -$727.4 million in Q4 2024.
- A 5-year average of -$520.2 million and a median of -$480.1 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value climbed 21.28% in 2022, then slumped 71.57% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$438.0 million in 2022, then increased by 3.2% to -$424.0 million in 2023, then tumbled by 71.57% to -$727.4 million in 2024, then increased by 8.27% to -$667.2 million in 2025, then gained by 12.95% to -$580.8 million in 2026.
- Business Quant data shows KURA's Enterprise Value at -$580.8 million in Q1 2026, -$667.2 million in Q4 2025, and -$549.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -584.73 Mn |
| 10 | Kura Oncology | 763.82 Mn | 763.82 Mn | 18.00 Mn | -580.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -580.82 Mn |
| Dec 31, 2025 | -667.24 Mn |
| Sep 30, 2025 | -549.67 Mn |
| Jun 30, 2025 | -630.73 Mn |
| Mar 31, 2025 | -658.19 Mn |
| Dec 31, 2024 | -727.40 Mn |
| Sep 30, 2024 | -455.30 Mn |
| Jun 30, 2024 | -491.52 Mn |
| Mar 31, 2024 | -527.12 Mn |
| Dec 31, 2023 | -423.96 Mn |
| Sep 30, 2023 | -452.59 Mn |
| Jun 30, 2023 | -476.98 Mn |
| Mar 31, 2023 | -405.90 Mn |
| Dec 31, 2022 | -437.99 Mn |
| Sep 30, 2022 | -427.78 Mn |
| Jun 30, 2022 | -450.26 Mn |
| Mar 31, 2022 | -480.08 Mn |
| Dec 31, 2021 | -517.96 Mn |
| Sep 30, 2021 | -543.45 Mn |
| Jun 30, 2021 | -567.49 Mn |